88Q.F 4BASEBIO PLC EO 1

Healthcare Biotechnology Frankfurt Exchange
5.70 EUR
Close of Nov 11, 2026
3.58 8.40
Market cap
EUR 88.3M
P/E
-
P/B
57.98x
ROE
-167.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 88Q.F undervalued?

Graham number

The Graham number of 4BASEBIO PLC EO 1 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

4BASEBIO PLC EO 1 fundamental analysis

No fundamental analysis for 4BASEBIO PLC EO 1 yet.

4BASEBIO PLC EO 1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About 4BASEBIO PLC EO 1

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for use in vaccines and therapeutics; oeDNA, a linear, double stranded DNA for genome…

Full company profile